Green Square Capital LLC lessened its stake in shares of AbbVie Inc (NYSE:ABBV) by 13.1% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 80,632 shares of the company’s stock after selling 12,180 shares during the period. AbbVie comprises about 1.1% of Green Square Capital LLC’s holdings, making the stock its 25th biggest position. Green Square Capital LLC’s holdings in AbbVie were worth $7,433,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Prime Capital Investment Advisors LLC bought a new position in AbbVie during the fourth quarter worth about $27,000. Penserra Capital Management LLC bought a new position in AbbVie during the fourth quarter worth about $32,000. Larson Financial Group LLC bought a new position in AbbVie during the fourth quarter worth about $37,000. Horrell Capital Management Inc. bought a new position in AbbVie during the fourth quarter worth about $41,000. Finally, Portfolio Solutions LLC bought a new position in AbbVie during the fourth quarter worth about $46,000. Institutional investors and hedge funds own 70.53% of the company’s stock.
ABBV stock opened at $79.82 on Tuesday. AbbVie Inc has a 12 month low of $75.62 and a 12 month high of $107.25. The company has a market capitalization of $118.00 billion, a PE ratio of 10.09, a PEG ratio of 1.62 and a beta of 1.14.
The company also recently disclosed a quarterly dividend, which was paid on Wednesday, May 15th. Stockholders of record on Monday, April 15th were given a $1.07 dividend. The ex-dividend date of this dividend was Friday, April 12th. This represents a $4.28 dividend on an annualized basis and a dividend yield of 5.36%. AbbVie’s dividend payout ratio (DPR) is currently 54.11%.
In other news, Vice Chairman Laura J. Schumacher sold 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $80.00, for a total value of $2,000,000.00. Following the completion of the transaction, the insider now directly owns 139,838 shares in the company, valued at $11,187,040. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Brian L. Durkin sold 475 shares of the firm’s stock in a transaction that occurred on Monday, March 25th. The shares were sold at an average price of $79.69, for a total transaction of $37,852.75. Following the completion of the transaction, the vice president now owns 9,121 shares of the company’s stock, valued at $726,852.49. The disclosure for this sale can be found here. Insiders sold 41,272 shares of company stock valued at $3,286,290 over the last 90 days. 0.08% of the stock is owned by company insiders.
ABBV has been the subject of a number of research reports. UBS Group reiterated a “neutral” rating and set a $91.00 target price (down previously from $97.00) on shares of AbbVie in a research report on Wednesday, January 23rd. Zacks Investment Research lowered shares of AbbVie from a “buy” rating to a “hold” rating in a research report on Wednesday, January 23rd. ValuEngine lowered shares of AbbVie from a “hold” rating to a “sell” rating in a research report on Friday, January 25th. Credit Suisse Group set a $79.00 target price on shares of AbbVie and gave the stock a “hold” rating in a research report on Friday, January 25th. Finally, Barclays reiterated a “hold” rating and set a $86.00 target price on shares of AbbVie in a research report on Thursday, February 14th. Six equities research analysts have rated the stock with a sell rating, eight have given a hold rating and five have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $94.95.
AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.
Featured Article: Quiet Period Expirations
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc (NYSE:ABBV).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.